JUL 22, 2020 12:29 PM PDT

Investigating a New Target Against Esophageal Cancer

WRITTEN BY: Jasper Cantrell

Esophageal cancer remains one of the most dangerous cancers in the world. Most therapies center around chemotherapy, radiotherapy, surgery, or a combination of these. Esophageal cancer has a low success rate with these treatments. However, research exposes new therapeutic targets every year.

One example that has developed from this is targeting the glycogen synthesis pathway. There is a clear decrease in glycogen levels in many cancers, so it stood to reason it would be a source of possible targeted therapies. A team from Kanazawa University in Japan studied it before and found that the protein GSK3β (glycogen synthase kinase 3β) might be a suitable target.

The team had previously identified that glycogen synthase (which makes glycogen from glucose), is inactivated by glycogen synthase kinase 3β. In esophageal cancer, GSK3β was more active than in healthy tissues and was associated with cancer progression. The team knew that GSK3β inhibition could suppress this pro-tumor activity but not how it did so. They began an investigation to figure out how GSK3β inhibition managed to suppress tumor growth.

They first confirmed that GSK3β levels were elevated in esophageal cancer versus healthy tissues. Inhibitors directed at GSK3β also impaired the growth of esophageal cancer cells, while healthy cells remained unaffected. These observations confirmed that GSK3β was an effective target for anti-cancer therapy.

The team knew that many cancer treatments work by impairing cancer growth by affecting the cell cycle, which usually resulted in the cell’s termination. They tested GSK3β inhibitors and found that they stalled cancer cells during the cell cycle. These cells were then confirmed to be terminated by apoptosis (a cell death pathway).

Finally, the team wanted to test the safety of GSK3β inhibitors in a mouse model. Application of GSK3β inhibitors to mice with tumors significantly slowed tumor growth, with the mice experiencing no adverse effects from the treatment.

This study provides substantial evidence supporting GSK3β inhibitors use as cancer therapeutics. The inhibitors managed to impair cell growth pathways by preventing the activation of GSK3β without harming healthy cells. One of the inhibitors tested is even in clinical trials, the final testing phase of new therapeutics.

The study concludes, “Taken together, the present study reinforces the notion that GSK3β is a potential therapeutic target in ESCC, thereby including this as another tumor type susceptible to GSK3β-targeted therapy.”

Sources: Nature Scientific Reports, Roswell Park Comprehensive Cancer Center

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 24, 2020
Cancer
A New Biomarker Candidate for Cancer Diagnostics
JUL 24, 2020
A New Biomarker Candidate for Cancer Diagnostics
One of the best tools in the fight against cancer is diagnostics. In 2018, colorectal cancer was the second most lethal ...
AUG 07, 2020
Cancer
How Down Syndrome genes safeguard against solid tumors
AUG 07, 2020
How Down Syndrome genes safeguard against solid tumors
Are people with Down syndrome protected from developing solid tumors in some way? So suggests new research published in ...
AUG 09, 2020
Cancer
Reducing post-surgery metastasis in colorectal cancer patients
AUG 09, 2020
Reducing post-surgery metastasis in colorectal cancer patients
Scientists have recently shown the successful reduction of metastasis in post-surgery colorectal cancer patients. The st ...
AUG 31, 2020
Cancer
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
AUG 31, 2020
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
Chemoresistance is a serious problem for many cancer therapies. Solutions to this problem are harder to come by than the ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
SEP 08, 2020
Cancer
The story of a very scary protein
SEP 08, 2020
The story of a very scary protein
New research from biochemists at the University of Alberta has identified a protein that triggers the growth of aggressi ...
Loading Comments...